The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Read more here.
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Zovegalisib (RLY-2608) is the first pan-mutant-selective PI3Kα inhibitor, binding a novel allosteric site distinct from ...
Ontario's FAST program aims to speed up access to breakthrough cancer drugs for patients by almost a full year sooner.1Itovebi offers a targeted treatment ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of ...
In 2025 alone, the agency issued over 50 oncology approvals([1]) , but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated ...
SwissTargetPrediction and PharmMapper were used to predict HSYA targets. GeneCards and OMIM databases were used to identify targets associated with DN. The STRING database was used to construct the ...
Gedatolisib targets HR+/HER2-, PIK3CA wild-type advanced breast cancer, with a PDUFA goal date of July 17, 2026. The drug's multi-target approach inhibits all four class 1 PI3K isoforms, mTORC1, and ...
Gedatolisib targets HR+/HER2-, PIK3CA wild-type advanced breast cancer, addressing a significant unmet need in this common subtype. The drug's multi-target inhibition of the PI3K/AKT/mTOR pathway may ...
Subgroup analyses suggested that patients had a lower risk of recurrence with aspirin use even if they had received neoadjuvant treatment, adjuvant chemotherapy, or both. Daily aspirin use in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results